Literature DB >> 9046955

Adjuvant treatment of colorectal cancer.

L B Saltz1, D P Kelsen.   

Abstract

The adjuvant therapy of colorectal cancer has seen many important advances in recent years. Chemotherapy improves long-term disease-free survival rates in high-risk patients with resected colon cancer. Combined modality therapy, using surgery, radiation therapy, and chemotherapy, improves both local control and survival in patients with stage II and III rectal cancer. We examine in detail the data on which current recommendations for adjuvant treatments are based. We also review some of the more promising experimental approaches currently under investigation.

Entities:  

Mesh:

Year:  1997        PMID: 9046955     DOI: 10.1146/annurev.med.48.1.191

Source DB:  PubMed          Journal:  Annu Rev Med        ISSN: 0066-4219            Impact factor:   13.739


  5 in total

1.  Development of a clinically feasible molecular assay to predict recurrence of stage II colon cancer.

Authors:  Yuqiu Jiang; Graham Casey; Ian C Lavery; Yi Zhang; Dmitri Talantov; Michelle Martin-McGreevy; Marek Skacel; Elena Manilich; Abhijit Mazumder; David Atkins; Conor P Delaney; Yixin Wang
Journal:  J Mol Diagn       Date:  2008-06-13       Impact factor: 5.568

Review 2.  Clinical value of prognosis gene expression signatures in colorectal cancer: a systematic review.

Authors:  Rebeca Sanz-Pamplona; Antoni Berenguer; David Cordero; Samantha Riccadonna; Xavier Solé; Marta Crous-Bou; Elisabet Guinó; Xavier Sanjuan; Sebastiano Biondo; Antonio Soriano; Giuseppe Jurman; Gabriel Capella; Cesare Furlanello; Victor Moreno
Journal:  PLoS One       Date:  2012-11-07       Impact factor: 3.240

3.  Locally aggressive colonic and rectal cancer--clinical trial.

Authors:  Victor Radu; Daniel Ion; Mihai Bogdan Serban; Mircea Ciurea
Journal:  J Med Life       Date:  2010 Jul-Sep

4.  Is early post-operative treatment with 5-fluorouracil possible without affecting anastomotic strength in the intestine?

Authors:  B M van der Kolk; B M de Man; T Wobbes; T Hendriks
Journal:  Br J Cancer       Date:  1999-02       Impact factor: 7.640

5.  Tumor-infiltrating effector cells of alpha-galactosylceramide-induced antitumor immunity in metastatic liver tumor.

Authors:  Takuya Osada; Hirokazu Nagawa; Yoichi Shibata
Journal:  J Immune Based Ther Vaccines       Date:  2004-07-13
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.